Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Short Interest Up 747.3% in July

Conduit Pharmaceuticals Inc. (NASDAQ:CDT) saw a significant growth in short interest in the month of July. As of July 15th, there was short interest totalling 619,400 shares, a growth of 747.3% from the June 30th total of 73,100 shares. Based on an average daily volume of 2,640,000 shares, the days-to-cover ratio is currently 0.2 days. Approximately 6.0% of the company’s stock are short sold.

Conduit Pharmaceuticals Trading Down 1.5 %

Shares of CDT traded down $0.00 on Friday, reaching $0.24. The company’s stock had a trading volume of 698,643 shares, compared to its average volume of 1,238,873. Conduit Pharmaceuticals has a twelve month low of $0.21 and a twelve month high of $25.00. The firm has a fifty day moving average of $1.60 and a 200-day moving average of $2.61.

Conduit Pharmaceuticals (NASDAQ:CDT) last announced its earnings results on Tuesday, May 14th. The company reported ($0.05) earnings per share (EPS) for the quarter.

Conduit Pharmaceuticals Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.